Oak Hill Bio, a clinical-stage rare disease therapeutics company, completed the acquisition of a pipeline of clinical and preclinical investigational therapeutics of Takeda Pharmaceutical. Financial terms were not disclosed. “Oak Hill has a significant opportunity to take these promising programs and advance them through clinical development to bring life-altering new medicines to patients in need. We are confident not only in these potentially transformative compounds, but also in the extraordinary team that has come together to deliver these innovative therapies,” Josh Distler, Oak Hill Bio President and CFO.